Trials / Completed
CompletedNCT00392197
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism-
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | 1 or 2 times a day, p.o., 6 - 24mg a day |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2006-10-25
- Last updated
- 2014-02-12
- Results posted
- 2014-02-12
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00392197. Inclusion in this directory is not an endorsement.